Phase 1 study of ibrutinib and the CXCR4 antagonist ulocuplumab in CXCR4-mutated Waldenstrom macroglobulinemia

Steven P. Treon, Kirsten Meid, Zachary R. Hunter, Catherine A. Flynn, Shayna R. Sarosiek, Carly R. Leventoff, Timothy P. White, Yang Cao, Aldo M. Roccaro, Antonio Sacco, Maria G. Demos, Maria Luisa Guerrera, Amanda Kofides, Xia Liu, Lian Xu, Christopher J. Patterson, Manit Munshi, Nicholas Tsakmaklis, Guang Yang, Irene M. Ghobrial, Andrew R. Branagan, and Jorge J. Castillo

Phase 1 study of ibrutinib and the CXCR4 antagonist ulocuplumab in CXCR4-mutated Waldenstrom macroglobulinemia

blood® 28 OCTOBER 2021 | VOLUME 138, NUMBER 17